Skip to main content

Improving pharmacovigilance using routinely collected data

In a recent BMJ editorial, Nicholas Moore and Bernard Begaud outline initiatives to improve pharmacovigilance in Europe. Such initiatives are essential to improving the safety of healthcare because current approaches to detection of serious adverse drug reactions (ADRs) have major limitations. Serious adverse drug reactions are often too rare to be detected in early clinical trials, and may not be detected through post-marketing surveillance for many years. This delay in identifying adverse drug reactions leaves clinicians unaware about the potential risks of the drugs they are prescribing, puts patients at risk of iatrogenic harm, and increases both healthcare costs and the costs of drug development.

The development of databases derived from electronic patient records and hospital administration systems could help to improve the detection of adverse drug reactions. In England, these databases include the General Practice Research Database (GPRD), The Health Improvement Network (THIN) and QResearch, all of which are derived from electronic primary care records; and the Hospital Episode Statistics (HES) database, which is derived from hospital patient administration systems and hospital discharge records.

To illustrate this potential, we used one primary care database (THIN) to investigate the association of myopathy and myalgia with the use of statins. Using a case-crossover design (in which each patient acts as their own control and side-effects are examined in the period while a patient is on a drug compared when they are not), it may have been possible to detect the association with statins as early as 1996 (see the figure below, which shows the relative risk of myopathy & myalgia by year in 16,591 patients using statins or fibrates from 1991–2005). A longer exposure period then allows more precise quantification of the size of the effect with narrowing of confidence intervals. The full results of this study can be viewed in an article published in the medical journal PLoS One.

For adverse drug reactions that result in hospital admission, Hospital Episode Statistics, which cover all inpatient and day case activity in England, offer a method for identifying these admissions. For example, between 1998–2005, the total number of hospital episodes for all diagnoses increased by 14% but the total number of hospital episodes associated with adverse drug reactions increased by 45%.[4] The increase in admissions associated with adverse drug reactions may have due to a number of factors: improving record keeping from increased awareness, a general increase in adverse drug reactions against a background of an increasingly elderly population, the introduction of new drugs, and poly-pharmacotherapy because of increased pressure to prescribe medication for long-term illnesses such as diabetes, heart disease and hypertension. More detailed coding, and better use of HES data and of similar systems elsewhere in Europe, could considerably improve our surveillance of ADRs, as well as allowing the evaluation of interventions to improve the safety of prescribing. These issues and the full results of this study are discussed in an article published in BMC Clinical Pharmacology.

Health systems throughout Europe are investing substantially in information and communication technologies, such as the National Programme for Information Technology in England's NHS. One consequence of this investment could be substantially improved methods of pharmacovigilance, allowing pan-European studies building on the many national studies we have seen to date. For example, the EU-ADR project aims to use data from several European countries to develop improved methods of pharmacovigilance. Coverage of larger populations than allowed by single country and single database studies also increases study power with the potential benefit of earlier and more effective detection of adverse drug reactions.

Source: Improving pharmacovigilance: Use of routinely collected data. BMJ 2010;340:c2403.


Popular posts from this blog

Can GPs issue private prescriptions to NHS patients?

The NHS prescription charge in England is currently £8.60 per item. At this level, many commonly prescribed drugs will cost less than the prescription charge and so some NHS patients may occasionally ask if they can have a private prescription rather than an NHS prescription.

In the past, some GPs have been advised that they could issue both an NHS FP10 and a private prescription, and let the patient decide which to use. But the British Medical Association's General Practice Committee has obtained legal advice that said under the current primary care contract, GPs in England may not issue a private prescription alongside or as an alternative to an NHS FP10 prescription. In any consultation where a GP needs to issue an FP10, the concurrent issue of a private prescription would be a breach of NHS regulations.

The issuing of a private prescription in such circumstances could also be seen as an attempt to deprive the NHS of the funds it would receive from the prescription charge. Fur…

What will Brexit mean for the NHS?

On the 29 March 2017, the Prime Minister of the UK Theresa May, formally notified the European Union (EU) Council President, Donald Tusk, of the UK’s intention to leave the EU. Theresa May’s letter to Donald Tusk triggers a two-year process during which the UK will have to negotiate both the terms of its exit from EU and the arrangements that will replace those we have had for over 40 years with the other member states of the EU. The consequences of the United Kingdom’s departure from the EU (commonly referred to as ‘Brexit’) will be wide-ranging and will affect all areas of UK’s society, including the National Health Service (NHS).

For the NHS, Brexit comes at a time when it faces many other major challenges. These include severe financial pressures, rising workload, increased waiting times for both primary care and specialist services, and shortages of health professionals in many key areas (such as in general practice and in emergency departments). The NHS also faces challenges fr…

Dr Demis Hassabis, Co-Founder and CEO of DeepMind, Speaks about AI in Healthcare

On 28 September 2017, I attended the Annual Institute of Global Health Innovation Lecture: Artificial General Intelligence and Healthcare, delivered by Dr Demis Hassabis, co-founder and CEO of Google DeepMind. Artificial intelligence is the science of making machines smart argued Dr Hassabis, so how can we make it improve the healthcare sector? Dr Hassabis then went on to describe the work that DeepMind was carrying out in healthcare in areas such as organising information, deep learning to support the reporting of medical images (such as scans and pathology slides), and biomedical science. Dr Hassabis also discussed the challenges of applying techniques such as reinforcement learning in healthcare. He concluded that artificial intelligence has great scope for improving healthcare; for example, by prioritising the tasks that clinicians had to carry out and by providing decision support aids for both patients and doctors. Dr Hassabis also discussed some of the ethical issues in using …